Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Medical Marijuana, Inc. (MJNA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0130-0.0001 (-0.76%)
At close: 03:58PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0131
Open0.0134
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0126 - 0.0135
52 Week Range0.0100 - 0.0400
Volume4,134,770
Avg. Volume5,508,240
Market Cap56.057M
Beta (5Y Monthly)0.78
PE Ratio (TTM)6.50
EPS (TTM)0.0020
Earnings DateAug 15, 2022 - Aug 19, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MJNA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • MEDICAL MARIJUANA INC
    LNN: Lowering target price to $132.00LINDSAY CORP has an Investment Rating of BUY; a target price of $132.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    Medical Marijuana, Inc. Subsidiary Kannaway Hosts Regional Conference in South Africa

    SAN DIEGO, CA, June 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary Kannaway® will be hosting its South Africa Regional Conference in Cape Town this Saturday, July 2, 2022. “Kannaway has experienced an incredible start in South Africa an

  • GlobeNewswire

    Medical Marijuana, Inc. Subsidiary Kannaway® Achieves Largest Revenue Month in Company History for Japan Division in May 2022

    SAN DIEGO, CA, June 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that in May its subsidiary Kannaway® has achieved its largest revenue month in the company’s history for its Japan division. According to one of the most recent industry reports, Japan’s CBD

  • GlobeNewswire

    Medical Marijuana, Inc. Subsidiary Kannaway® Celebrates Recent Federal Court Ruling on Delta-8 THC; Launches New Hemp Products

    SAN DIEGO, CA, May 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that it applauds the Ninth U.S. Circuit Court of Appeals for deeming Delta-8 THC, a compound found in hemp, to be federally legal under the 2018 Farm Bill. In celebration of this announcement

Advertisement
Advertisement